~~<i id='412EF05844'><strike id='412EF05844'><tt id='412EF05844'><pre id='412EF05844'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

comprehensive

author：comprehensive 2025-09-27 09:45:24 - browse：7

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Medicare inequities exacerbate Puerto Rico’s health disparities

hotspot

leisure time

entertainment

leisure time

MadrigalCEOBillSiboldsaysthecompanyis"interestedinthepatientswhoaremostinneed."MadrigalPharmaceutica

WSS

PBM reform efforts get punted in Congress

Obesity drugs seen as possible treatment for liver disease MASH

Air quality improving but still lags in Black, Hispanic communities

Alabama frozen embryo ruling has major implications for IVF clinics

He's a Nobel laureate. Critics say he was misleading on Covid

In utero gene editing: an explainer

explore

comprehensive

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Air quality improving but still lags in Black, Hispanic communities

Medicare proposal to cover medical devices draws a mixed reaction

NIH study of ME/CFS points to clear biological hallmarks

How to save PrEP access — and even expand it

A deep dive into Applied Therapeutics’ data, and questions on Cassava

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Change Healthcare cyberattack prompts Medicare loan program

Guidelines to prevent youth baseball injuries need more muscle

Amylyx ALS drug failure raises questions and concerns

leisure time

The drug industry has found itself all alone in Washington

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

New documents shed light on MD Anderson Cancer Institute feud

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

With competition flaring, obesity drug hits goal in liver disease study

leisure time

leisure time

entertainment

leisure time